The use of GPR55 as a therapeutic target for managing motor deficits in PD has been proposed, with research focusing on the effects of GPR55 selective ligands in PD rat models (Fatemi et al., 2021; Sánchez-Zavaleta et al., 2023). This evidence concerns the gene GPR55 and Parkinson disease.